Jak1-STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis.

Bone and soft tissue tumors (BSTT) are relatively poorly understood, hampering the development of effective therapies. Here we report a role for the ubiquitin-specific protease 6 (USP6)/TRE17 oncogene, which is overexpressed upon chromosome translocation in various human tumors, including aneurysmal bone cyst (ABC), and the related benign lesion nodular fasciitis. Ectopic expression of USP6 is known to drive formation of tumors, which recapitulate key features of ABC and nodular fasciitis; however, the identity of USP6's relevant substrates has been obscure. Here we report that the Jak1-STAT3 signaling pathway serves as an essential effector of USP6 in BSTT formation. We found that USP6 directly deubiquitinated Jak1, leading to its stabilization and activation of STAT3. The tumorigenic potential of USP6 was attenuated significantly by CRISPR-mediated deletion of Jak1 or STAT3, or by administration of a Jak family inhibitor. Analysis of primary clinical samples of nodular fasciitis confirmed the activation of a Jak1-STAT3 gene signature in vivo Together, our studies highlight Jak1 as the first identified substrate for USP6, and they offer a mechanistic rationale for the clinical investigation of Jak and STAT3 inhibitors as therapeutics for the treatment of bone and soft tissue tumors along with other neoplasms driven by USP6 overexpression. Cancer Res; 76(18); 5337-47. ©2016 AACR.

[1]  M. Pitman,et al.  Nodular fasciitis clinically presenting as a sarcoma , 2015, Diagnostic cytopathology.

[2]  M. Chou,et al.  TRE17/USP6 regulates ubiquitylation and trafficking of cargo proteins that enter cells by clathrin-independent endocytosis , 2014, Journal of Cell Science.

[3]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[4]  R. Jove,et al.  Targeting JAK1/STAT3 Signaling Suppresses Tumor Progression and Metastasis in a Peritoneal Model of Human Ovarian Cancer , 2014, Molecular Cancer Therapeutics.

[5]  M. Karin,et al.  IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. , 2014, Seminars in immunology.

[6]  J. Zucman‐Rossi,et al.  Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma , 2013, Oncoimmunology.

[7]  Surinder Paul,et al.  Nodular fasciitis: a diagnostic challenge. , 2013, Indian journal of pathology & microbiology.

[8]  Zhao-Hui Wu,et al.  When ubiquitin meets NF-κB: a trove for anti-cancer drug development. , 2013, Current pharmaceutical design.

[9]  J. O’Shea,et al.  Janus kinase inhibitors in autoimmune diseases , 2013, Annals of the rheumatic diseases.

[10]  Alexander Varshavsky,et al.  The ubiquitin system, an immense realm. , 2012, Annual review of biochemistry.

[11]  A. Tefferi.  JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. , 2012, Blood.

[12]  M. Chou,et al.  Atypical Mechanism of NF-κB activation by TRE17/Ubiquitin-Specific Protease 6 (USP6) oncogene and its requirement in tumorigenesis , 2011, Oncogene.

[13]  M. Chou,et al.  Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion , 2011, Laboratory Investigation.

[14]  A. Tefferi,et al.  JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. , 2011, Blood reviews.

[15]  M. Karin,et al.  Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage , 2011, Annals of the rheumatic diseases.

[16]  M. Chou,et al.  TRE17/Ubiquitin-specific Protease 6 (USP6) Oncogene Translocated in Aneurysmal Bone Cyst Blocks Osteoblastic Maturation via an Autocrine Mechanism Involving Bone Morphogenetic Protein Dysregulation* , 2010, The Journal of Biological Chemistry.

[17]  B. Druker,et al.  CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. , 2010, Blood.

[18]  M. Chou,et al.  TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappa B , 2012 .

[19]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[20]  Michael J. Clague,et al.  Emerging roles of deubiquitinases in cancer‐associated pathways , 2010, IUBMB life.

[21]  David Komander,et al.  Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.

[22]  Keith D Wilkinson,et al.  Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. , 2009, Annual review of biochemistry.

[23]  Tony Hunter,et al.  Degradation of activated protein kinases by ubiquitination. , 2009, Annual review of biochemistry.

[24]  A. Tefferi,et al.  CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients , 2009, Leukemia.

[25]  J. Keats,et al.  Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling , 2008, Nature Immunology.

[26]  B. Saccomanni.  Aneurysmal bone cyst of spine: a review of literature , 2008, Archives of Orthopaedic and Trauma Surgery.

[27]  Y. Chung,et al.  Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers , 2008, Clinical Cancer Research.

[28]  M. Schmitz,et al.  NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer , 2007 .

[29]  J. Cottalorda,et al.  Modern concepts of primary aneurysmal bone cyst , 2007, Archives of Orthopaedic and Trauma Surgery.

[30]  J. Cottalorda,et al.  Current treatments of primary aneurysmal bone cysts , 2006, Journal of pediatric orthopedics. Part B.

[31]  M. Chou,et al.  Calcium/Calmodulin Regulates Ubiquitination of the Ubiquitin-specific Protease TRE17/USP6* , 2005, Journal of Biological Chemistry.

[32]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Fletcher,et al.  Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes , 2005, Oncogene.

[34]  M. Chou,et al.  The TBC (Tre-2/Bub2/Cdc16) Domain Protein TRE17 Regulates Plasma Membrane-Endosomal Trafficking through Activation of Arf6 , 2004, Molecular and Cellular Biology.

[35]  J. Fletcher,et al.  USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. , 2004, The American journal of pathology.

[36]  Corinne M. Silva.  Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis , 2004, Oncogene.

[37]  J. Fletcher,et al.  USP6 (Tre2) Fusion Oncogenes in Aneurysmal Bone Cyst , 2004, Cancer Research.

[38]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[39]  M. Chou,et al.  The TRE17 Oncogene Encodes a Component of a Novel Effector Pathway for Rho GTPases Cdc42 and Rac1 and Stimulates Actin Remodeling , 2003, Molecular and Cellular Biology.

[40]  D. Haber,et al.  The Tre2 (USP6) oncogene is a hominoid-specific gene , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  W. Leonard.  Role of Jak Kinases and STATs in Cytokine Signal Transduction , 2001, International journal of hematology.

[42]  W. Leonard,et al.  Cytokine receptor signaling pathways. , 2000, The Journal of allergy and clinical immunology.

[43]  C. Croce,et al.  A novel transcriptional unit of the tre oncogene widely expressed in human cancer cells. , 1992, Oncogene.

[44]  I. Pommepuy,et al.  [Nodular fasciitis: case report and review of the literature]. , 2013, Chirurgie de la main.

[45]  M. Chou,et al.  The TRE17/USP6 oncogene: a riddle wrapped in a mystery inside an enigma. , 2012, Frontiers in bioscience.

[46]  M. Karin,et al.  NF-κB and STAT3 – key players in liver inflammation and cancer , 2011, Cell Research.

[47]  M. Karin,et al.  Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. , 2009 .

[48]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[49]  M. Schmitz,et al.  NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. , 2007, Current medicinal chemistry.

[50]  W. Leonard,et al.  Jaks and STATs: biological implications. , 1998, Annual review of immunology.

[51]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .